International haemovigilance: what have we learned and what do we need to do next?

E. M. Wood, A. L. Ang, A. Bisht, P. H. Bolton-Maggs, A. G. Bokhorst, O. Flesland, K. Land, J. C. Wiersum-Osselton, M. R. Schipperus, P. Tiberghien, B. I. Whitaker

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

The International Haemovigilance Network (IHN) defines haemovigilance as ‘a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence’. IHN, the International Society of Blood Transfusion and World Health Organisation work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion-transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety.

Original languageEnglish
Number of pages10
JournalTransfusion Medicine
DOIs
Publication statusAccepted/In press - 6 Feb 2019

Keywords

  • adverse reaction
  • biovigilance
  • blood transfusion
  • haemovigilance
  • human factors

Cite this

Wood, E. M., Ang, A. L., Bisht, A., Bolton-Maggs, P. H., Bokhorst, A. G., Flesland, O., ... Whitaker, B. I. (Accepted/In press). International haemovigilance: what have we learned and what do we need to do next? Transfusion Medicine. https://doi.org/10.1111/tme.12582
Wood, E. M. ; Ang, A. L. ; Bisht, A. ; Bolton-Maggs, P. H. ; Bokhorst, A. G. ; Flesland, O. ; Land, K. ; Wiersum-Osselton, J. C. ; Schipperus, M. R. ; Tiberghien, P. ; Whitaker, B. I. / International haemovigilance: what have we learned and what do we need to do next?. In: Transfusion Medicine. 2019.
@article{b00edd89789441debf2a5fb96c3267c8,
title = "International haemovigilance: what have we learned and what do we need to do next?",
abstract = "The International Haemovigilance Network (IHN) defines haemovigilance as ‘a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence’. IHN, the International Society of Blood Transfusion and World Health Organisation work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion-transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety.",
keywords = "adverse reaction, biovigilance, blood transfusion, haemovigilance, human factors",
author = "Wood, {E. M.} and Ang, {A. L.} and A. Bisht and Bolton-Maggs, {P. H.} and Bokhorst, {A. G.} and O. Flesland and K. Land and Wiersum-Osselton, {J. C.} and Schipperus, {M. R.} and P. Tiberghien and Whitaker, {B. I.}",
year = "2019",
month = "2",
day = "6",
doi = "10.1111/tme.12582",
language = "English",
journal = "Transfusion Medicine",
issn = "0958-7578",
publisher = "Wiley-Blackwell",

}

Wood, EM, Ang, AL, Bisht, A, Bolton-Maggs, PH, Bokhorst, AG, Flesland, O, Land, K, Wiersum-Osselton, JC, Schipperus, MR, Tiberghien, P & Whitaker, BI 2019, 'International haemovigilance: what have we learned and what do we need to do next?' Transfusion Medicine. https://doi.org/10.1111/tme.12582

International haemovigilance: what have we learned and what do we need to do next? / Wood, E. M.; Ang, A. L.; Bisht, A.; Bolton-Maggs, P. H.; Bokhorst, A. G.; Flesland, O.; Land, K.; Wiersum-Osselton, J. C.; Schipperus, M. R.; Tiberghien, P.; Whitaker, B. I.

In: Transfusion Medicine, 06.02.2019.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - International haemovigilance: what have we learned and what do we need to do next?

AU - Wood, E. M.

AU - Ang, A. L.

AU - Bisht, A.

AU - Bolton-Maggs, P. H.

AU - Bokhorst, A. G.

AU - Flesland, O.

AU - Land, K.

AU - Wiersum-Osselton, J. C.

AU - Schipperus, M. R.

AU - Tiberghien, P.

AU - Whitaker, B. I.

PY - 2019/2/6

Y1 - 2019/2/6

N2 - The International Haemovigilance Network (IHN) defines haemovigilance as ‘a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence’. IHN, the International Society of Blood Transfusion and World Health Organisation work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion-transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety.

AB - The International Haemovigilance Network (IHN) defines haemovigilance as ‘a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence’. IHN, the International Society of Blood Transfusion and World Health Organisation work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion-transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety.

KW - adverse reaction

KW - biovigilance

KW - blood transfusion

KW - haemovigilance

KW - human factors

UR - http://www.scopus.com/inward/record.url?scp=85061307881&partnerID=8YFLogxK

U2 - 10.1111/tme.12582

DO - 10.1111/tme.12582

M3 - Review Article

JO - Transfusion Medicine

JF - Transfusion Medicine

SN - 0958-7578

ER -